Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. (Q40372701)
Jump to navigation
Jump to search
scientific article published on September 2005
Language | Label | Description | Also known as |
---|---|---|---|
English | Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. |
scientific article published on September 2005 |
Statements
Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy (English)
Ronald Yap
Dorina Veliceasa
Urban Emmenegger
Robert S Kerbel
Laura M McKay